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ABSTRACT 
Zopiclone, a cyclopyrolone, is a non-benzodiazepine derivative used as a hypnotic agent in the treatment of short term insomnia. The main 
objective of the present investigation was to formulate a pharmaceutically active stable and bioequivalent immediate release (IR) tablets of 
zopiclone using wet granulation method. The prepared formulations were evaluated using various physical parameters, equipment, dissolution 
study and drug release profile.  The basic approach used in development of zopiclone IR tablets was that the use of superdisintegrants as like 
Corn starch (maize) and Sodium starch glycolate which provide instant disintegration after administration. In-vitro dissolution testing study was 
carried out for 1 hours using 0.1N HCl in a dissolution apparatus for evaluation of Drug release. On the basis of the dissolution profile, F3 gives a 
better result and were found 100 % release in just 20 minutes and also found that as the polymer ratio were increases the drug release rate also 
increased from the formulation. 
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INTRODUCTION 
Solid Oral Dosage Form 
The oral route is the one most frequently used for drug 
administration. Oral dosage forms are usually intended for 
systemic effects resulting from drug absorption through the 
various epithelia and mucosa of the gastrointestinal tract. 
Compared with other routes, the oral route is the simplest, 
most convenient and safest means of drug administration. 
The most popular oral dosage forms are tablets, capsules. 
Tablets are prepared by compression and contain drugs and 
formulation additives, which are included for specific 
functions, such as disintegrants which promote tablet break-
up into granules and powder particles in the gastrointestinal 
tract, thereby facilitating drug dissolution and absorption. 
Tablets are often coated, either to provide a protection 
against environmental factors for drug stability purposes or 
to mask unpleasant drug taste, as well as to protect drugs 
from the acid conditions of the stomach 1. 
Immediate Release Tablet: 
Immediate release solid oral dosage forms are classified as 
either having rapid or slow dissolution rates i.e includes any 
formulation in which the rate of release of drug from the 
formulation and/or the absorption of drug, is neither 
appreciably, nor intentionally, retarded by galenic 
manipulations. Immediate release dosage forms are those for 
which ≥85% of labelled amount dissolves within 30 min. For 
immediate release tablets, the only barrier to drug release is 
simple disintegration or erosion stage, which is generally 
accomplished in less than one hour 2. In the present case, 
immediate release may be provided for by way of an 
appropriate pharmaceutically acceptable diluents or carrier, 
which diluents or carrier does not prolong, to an appreciable 
extent, the rate of drug release and/or absorption.  
In this context, the term “release” includes the provision (or 
presentation) of drug from the formulation to the 
gastrointestinal tract, to body tissues and/or into systemic 
circulation. For gastrointestinal tract release, the release is 
under pH conditions such as pH=1to3, especially at, or about, 
pH=1. 
An immediate release pharmaceutical preparation offers: 
Improved compliance/added convenience, Improved 
stability, Allows high drug loading, Adaptable and amenable 
Bhatt et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):132-137 
ISSN: 2250-1177                                                                                  [133]                                                                                 CODEN (USA): JDDTAO 
to existing processing and packaging machinery and Cost- 
effective 3,4,5,6,7. 
In vitro dissolution testing of solid dosage forms is the most 
frequently used biopharmaceutical, test method in 
formulation development. It is used from the start of dosage 
form development and in all subsequent phases 8. 
Dissolution testing is a requirement for all solid oral dosage 
forms and is used in all phases of development for product 
release and stability testing. It is a key analytical test used for 
detecting physical changes in an active pharmaceutical 
ingredient (API) and in the formulated product.  At early 
stages of development, in-vitro dissolution testing guides the 
optimization of drug release from formulations.  Over the 
past 50 years, dissolution testing has also been employed as 
a quality control (QC) procedure, in R&D to detect the 
influence of critical manufacturing variables and in 
comparative studies for in-vitro/in-vivo correlation 
(IVIVC).The FDA guidance on dissolution testing for 
immediate release solid oral dosage forms includes the use 
of the Biopharmaceutics Classification System (BCS) 
guidelines for biorelevant dissolution tests, which is based 
upon API solubility and permeability. The FDA guidance on 
scale-up and post approval changes (SUPAC) for immediate 
release oral dosage forms recommends the use of  in-vitro 
dissolution to justify post-approval changes 9,10,11,12 .   
Zopiclone is used as a hypnotic agent in the short-term 
management of insomnia. Molecularly it is a pyrrolopyrazine 
derivative of cyclopyrrolone family. Cyclopyrrolone are 
distinct from benzodiazepines in structure, they have similar 
activity to that of benzodiazepines. Like diazepam, its actions 
are mediated by enhancement of the activity of 
gammaaminobutyric acid (GABA) in the brain. Zopiclone is 
reported to bind to the benzodiazepine receptor component 
of the GABA receptor complex but at a different site to the 
benzodiazepines. Its absorption time is approximately 2 
hours with a bioavailability of 70% and the elimination half-
life is 5 hours. It has a short duration of action. The usual oral 
dose is 7.5 mg before bed. In elderly patients, treatment 
should start with a dose of 3.75 mg before bed. Reduced 
doses are also recommended in patients with hepatic or 
renal impairment 13. 
MATERIALS AND METHOD 
Materials 
Zopiclone was received as a gift sample from Hetero 
Healthcare Ltd. Lactose monohydrate, Dibasic calcium 
phosphate, Corn starch(maize), Sodium starch glycolate, 
Magnesium stearate, Hypromellose(HPMC E-5), Ethyl 
cellulose, Diethyl phthalate, Talc, White opaspray K-1-7000-
S(methanol,TiO2,HPMC15cps) and Iso propyl alcohol were 
procured from Central Drug House ltd., New Delhi and Loba 
Chemie Pvt. Ltd., Mumbai.  
Method of preparation: 
In this present work the formulation was prepared by wet 
granulation method. 
 
Table 1: Formulation of zopiclone tablet 
S.NO. INGREDIENT F1 (mg/tab.) F2 (mg/tab.) F3 (mg/tab.) 
1 Zopiclone 7.50 7.50 7.50 
2 Lactose monohydrate 30.80 30.80 30.80 
3 Dibasic calcium phosphate 53.50 58.25 60.44 
4 Corn starch(maize) 57.25 55.00 55.50 
5 Corn starch(maize) 7.95 6.95 4.95 
6 Purified Water q.s. q.s. q.s. 
7 Sodium starch glycolate 3.00 4.00 5.00 
8 Magnesium stearate 5.00 2.50 1.70 
9 Total Weight 165.00 165.00 165.00 
Note- In the above formulation chart corn starch used two times as a binder and as a disintegrant in different ratios. 
 
Table 2: Formulation chart for the coating solution of 
zopiclone tablet 
S.N. Ingredient Quantity 
1 Hypromellose(HPMC E-5) 2.825 
2 Ethyl cellulose 0.925 
3 Diethyl phthalate 0.775 
4 Talc 1.625 
5 White opaspray K-1-7000-S 
(Methanol,TiO2,HPMC15cps) 
4.85 
6 Iso propyl alcohol q.s. 
7 Water q.s. 
 
Wet Granulation Method: 
Wet granulation is the process in which a liquid is added to a 
powder in a vessel equipped with any type of agitation that 
will produce agglomeration or granules. It is the oldest and 
most conventional method of making tablets. Although it is 
the most labor-intensive and most expensive of the available 
methods, it persists because of its versatility. The possibility 
of moistening powders with a variety of liquids, which can 
also act as carriers for certain ingredients, thereby 
enhancing the granulation characteristics, has many 
advantages. Granulation by dry compaction has many 
limitations. It does not lend itself to all tablet formulations 
because it depends on the bonding properties of dry 
powders added as a carrier to the drug thereby increasing 
the size of the tablet. In wet granulation, the bonding 
properties of the liquid binders available is usually sufficient 
to produce bonding with a minimum of additives. Wet 
granulation is a versatile process and its application in tablet 
formulation is unlimited 14, 15. 
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Wet granulation process16  
 
Coating Process of tablet:  
- Took IPA and water according to specification and mixed 
them, then add hypromellose and shaked for 30 min. 
- Then add ethyl cellulose and mix for 10 min. 
- After that add diethyl phthalate, talc, and white opaspray k-
1-7000-s and shaked for 30 min 17. 
Preformulation studies  
Before development of any formulation it is mandatory to 
carry out pre-formulation studies to determine any changes 
in the drug characteristics and suitability of a drug candidate 
for formulation development. Preformulation testing is an 
investigation of physical and chemical properties of a drug 
substance alone and when combined with excipients. It is the 
first step in the rational development of dosage forms. 
Drug Characterization: 
The drug was characterized and identified by spectroscopic 
analysis in the present study. The studies carried out include 
FT-IR, UV, Specific optical rotation, Sulphated ash, Assay, and 
Melting range. 
Drug Solubility: 
Solubility may be defined as the spontaneous interaction of 
two or more substances to form a homogeneous dispersion. 
The solubility of Zopiclone was studied in various aqueous 
and non-aqueous solvents. 10mg drug was taken in 10 ml of 
water, acetone, alcohol, methylene chloride, and dilute 
mineral at room temperature in screw-capped test tubes and 
shaken for 24 hours in wrist action shaker (York, India). The 
solubility was considered as soluble and what was insoluble.   
Particle size analysis: 
Bulk flow, formulation homogeneity, and surface-area 
controlled processes such as dissolution and chemical 
reactivity are directly affected by size, shape and surface 
morphology of the drug particles. The particle size analysis 
of Zopiclone involves the mechanical shaking of sample 
through a series of successively smaller sieves. Apparatus 
used for particle size analysis is mechanical shaker with 
vibratory motion.  
Angle of Repose: 
Angle of repose is defined as the maximum angle possible 
between the surface of pile of powder and the horizontal 
plane. The angle of repose calculated as:  
Angle of repose = Tan-1 (h/r)                              (Where, h=height of pile, 
r = radius of pile) 
Bulk Density Determination: 
Weighed quantity of powder (W) was taken in a graduated 
measuring cylinder and volume (V0) was measured. Bulk 
Density was calculated as: 
Bulk Density = Weight of powder/ Volume of powder (g/ml) 
Tapped Density Determination: 
Weighed quantity of powder was taken in a graduated 
cylinder and the volume was measured (V0). The graduated 
cylinder was fixed in the tapped densitometer and tapped for 
500, 750, and 1250 times until the difference in the volume 
after consecutive tapping was less than 2%. The final reading 
was denoted by (VF), the volume of blend was used to 
calculate the Tapped density, Hausner’s ratio, and Carr’s 
index. Taped Density calculated as: 
Tapped density = Weight of powder/ Final Volume of powder (g/ml) 
Hausner’s Ratio: 
Hausner’s ratio indicates the flow properties of the powder 
and measured by the ratio of tapped density to bulk density. 
Hausner’s ratio calculated as: 
Hausner’s Ratio = Tapped density/ Bulk density (H.R =VF/V0) 
Where, VF = Final volume, V0 = Initial volume. 
Carr’s Index: 
Carr’s index is also known as the compressibility index. It is 
directly related to the relative flow rate, cohesiveness and 
particle size. It is simple method of predicting powder flow. 
Carr’s Index calculated as: 
Carr’s Index = (Tapped Density – Bulk Density)/ Tapped Density x 100 
Preparation of Calibration curve of zopiclone: 
100 mg of zopiclone was accurately weighed and transferred 
to previously dried 100 ml volumetric flask. Drug was 
dissolved in 0.1N HCl solution. The solution was suitably 
diluted with 0.1NHCl solution to get standard concentration 
of 2, 4, 6, 8, 10, 12, 14, and 16 µg/ ml. absorbance was 
measured at 303 nm UV visible spectrophotometer.  
Pre-compression characterization 
There were the primary requirements to determine whether 
the specific material was suitable for the targeted 
formulation or not and the aim was to formulate the tablet 
formulation with wet granulation method, so it was 
mandatory to know about the bulk density, tapped density, 
Carr’s index, Hausner’s ratio and angle of repose as those 
were the necessary requirement while choosing any material 
for its dosage form and formulation. All the parameters as 
Bulk Density, Tapped Density, Carr’s index, Hausner’s ratio, 
Angle of Repose for various tablet formulation were 
evaluated and the result clearly indicates its suitability of the 
material to be selected for the formulation, results shown in 
Table 3. 
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Evaluation parameter of prepared immediate release 
tablet 
Weight: Weight of formulated immediate release tablet was 
determined by weighing balance (Mettler Toledo). 
Thickness: Thickness of tablets was measured by varnier 
caliper (Mitutoyo Corporation, Japan) and average was 
calculated. 
Hardness: The hardness of the tablets from each batch was 
measured by using hardness tester (Dr. Schluniger). 
Tablet friability: The friability of the tablets was measured 
in a Roche friabilator (Electrolab). Tablets of a known weight 
(W0) or a sample of 20 tablets are de dusted in a drum for a 
fixed time (100 revolutions) and weighed (W) again. 
Percentage friability was calculated from the loss in weight 
as given in equation as below. The weight loss should not be 
more than 1%. 
Determination was made in triplicate. 
F = (W initial) - (W final)/ (W initial)×100 
Where W initial = Initial weight of tablets. 
W final = Final weight of tablets 
Disintegration test: Disintegration is evaluated to ensure 
that the drug substance is fully available for dissolution and 
absorption from the gastrointestinal tract. In disintegration 
test, measured using tablet disintegration test apparatus 
(Electrolab, India) using distilled water without disk at room 
temperature (37±2°C). 
Weight variation test: Twenty tablets were selected 
randomly and weighed individually. Average weight of 
tablets were calculated and compared with that of the 
individual tablets. Weight not more than two of the 
individual weight deviate from the average weight by more 
than the percentage shown in table. 
Content Uniformity: This test is performed to maintain the 
uniformity of weight of  each  tablet  which  should  be  in  the  
prescribed  range  according  to  the  Indian Pharmacopoeia 
.The content uniformity  test  is mandatory  for tablets whose 
average weight is below 50mg. This test is performed by 
preparing standard solution of pure drug and sample 
solution solution of prepared formulation. 
Standard solution: Weighed accurately about 50 mg of 
standard zopiclone, dissolved  and diluted  to 100ml with 0.1 
N HCl. Diluted 3 ml of this solution to 100 ml with 0.1 N HCl. 
Sample solution: One tablet of zopiclone 7.5mg transferred 
in to a 100ml volumetric flask and add 80 ml of 0.1 N HCl, 
placed in an ultrasonic bath for 10 minutes until total 
disintegration of powder, makes up with HCl 0.1 N, shaked 
and filtered. Diluted the 5 ml of this solution to 25 ml with 
0.1N HCl. 
Procedure: Determined the absorbance of standard and 
sample solution at 303nm against 0.1 N HCl as a blank. Then 
calculate the content of zopiclone in the sample with the data 
obtained. 
In-vitro drug release 
In the present study dissolution profiles of Zopiclone tablets 
were determined using the Dissolution Test apparatus USP-2 
set with a paddle speed of 50rpm. Dissolution was tested in 
0.1 N HCl, Dissolution was performed in 500 ml, at 37±0.5°C; 
5 ml aliquot was withdrawn, at the 5, 10, 15, and 20 min with 
5minutes interval, and filtered through Whatmann filter 
paper. From these samples, 1ml taken into test tube volume 
made up with the same medium up to 10 ml and the drug 
solution absorbance was analyzed at 303nm in 1cm cuvette 
using UV-Visible spectrophotometer (Shimadzu-1800, 
Japan). 
Limit- Not less than 80% of labeled amount of zopiclone was 
dissolved after 15min. 
RESULT AND DISCUSSION 
Drug Characterization 
Identification by IR:  The infrared absorption spectrum of a 
sample should concordant with working standard spectrum 
of zopiclone. 
Identification by UV absorbance:  The solution shows 
absorption maximum at 303nm and specific absorbance at 
the maximum is 340 to 380. 
In the above study of drug characterization different 
parameters of drug were carried out including identification, 
related substance(0.17%), sulphated ash (0.04%),optical 
rotation (-0.05°to+0.05°), assay (99.51%), and melting 
point(177.2°C) by different method and the result was found 
to be acceptable. 
Further this was characterized for drug solubility study in 
the different solvent including water, acetone, alcohol, 
methylene chloride, and dilute mineral. Later after it was 
observed that zopiclone was soluble in methylene chloride 
and dilute mineral, sparingly soluble in acetone, and 
insoluble in water and alcohol.  
Particle size analysis of zopiclone was performed using 
vibratory shifter and the result was found to be within limit 
and had more fines that were determined to be 91.885%. 
Bulk characterization was carried out to observe the flow 
property of active drug that have great effect during 
formulation process. This includes bulk density 
(0.66gm/ml), tapped density (0.86gm/ml), Hausner’s ratio 
(1.30), Carr’s index (23.25%), and angle of repose (26°). The 
result of bulk characterization was found to be acceptable 
and had good flow property. 
The drug-excipient interaction was carried out by preparing 
different ratios of drug and excipient, and it was determined 
on the different temperature and relative humidity condition 
to find out the interaction and related impurities, water 
content and appearance of the drug and excipient. It was 
observed that at different condition all parameter was within 
limit and found to be compatible. 
Calibration curve of zopiclone was prepared. In this the 
absorbance of standard solution of zopiclone at 0-16 µg/ml 
were plotted as absorbance v/s concentration which gave 
almost a straight line passing from the origin with 
regression-coefficient o.989. So it followed Beer’s and 
Lambert’s law at the concentration range of 0-16 µg/ml. 
(Shown in figure no. 1) 
 
 
Figure 1: Standard curve of zopiclone
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Figure 2: FTIR spectra of zopiclone 
 
In the study of pre- compression characterization there were 
all the parameter as bulk density, tapped density, Carr’s 
index, Hausner’s ratio, and angle of repose were determined 
and found (shown in table no.3). Particle size analysis was 
also performed (shown in table no. 4). Here all parameter 
were found to be within limit and suitable for the further 
process of formulation. 
 
Table 3: Pre-compression characterization 
S.No. BulkDensity 
(gm/cm3 )  
TappedDensity 
(gm/cm3 ) 
Carr’sIndex Hausner’sRatio Angleof 
Repose 
F1 0.676±0.12 0.789±0.05 12.768±1.0% 1.163±0.05 32.24°±0.08 
F2 0.649±0.06 0.781±0.08 16.883±2.0% 1.203±0.03 32.00°±0.06 
F3 0.612±0.08 0.769±0.06 20.408±3.0% 1.256±0.06 29.19°±0.05 
n=3 
Table 4: Particle size analysis of granules 
S. No.                                        Sieve No. 
20# 40# 60# 80# 100# 
F1 18.16% 7. 32% 11.325% 4.78% 38.642% 
F2 16.29 % 6.425% 13.268% 6.42% 41.66% 
F3 17 % 5.36% 14.48% 7.36% 50.32% 
 
Post-compression characterization was performed and the parameter evaluated were average weight, thickness, hardness, 
friability,disintegration, and weight variation, the drug content, and all these parameter were found to be within limit and 
formulation F3 gave best result as per the objective of this project. (Shown in table no. 5) 
 
Table 5: Post-compression characterization 
PARAMETER                       FORMULATION 
F1 F2 F3 
 Avg. Weight(Mg) 174±3.2 174±3.7 176±3.9 
Thickness (mm) 3.66±0.4 3.85±0.7 3.65±0.9 
   Hardness(N) 151±10.1 147.4±8.2 149.36±8.5 
Friability(%W/W) 0.424±0.02 0.567±0.04 0.437±0.03 
Disintegration  time(Min-Sec) 3.00±0.17 2.50±0.13 2.40±0.16 
Weight Variation(%) 2.84±0.25 3.97±0.30 3.40±0.27 
Content Uniformity(%) 99.18±0.37 100.08±0.35 105.32±0.29 
           n=3 
In the present work in-vitro studies were performed and 
observed that in formulation F1 when used 3% 
superdisintigrant the drug release was to be found 
72.36±0.3% after 15 min. and was below the limit. Further 
increased the concentration of superdisintegrant in the 
formulation F2 by 4% and the release of drug were found to 
be 75.39±0.5% after 15 min. and 99.51±0.7% after 20 min. 
and this was also not satisfactorily. At last in the formulation 
F3, 5% of superdisintegrant was used and found to be 
82.06±0.5% after 15 min. and 100.02±0.6% after 20 min. 
and this was denoted as the best and final formulation. After 
dissolution studies it was observed that on increasing the 
content of superdisintigrant the release of drug was also 
increased. Since Zopiclone is acidic in nature and its 
absorption window is stomach, so it released the drug in the 
stomach. The Drug Release Profile of Immediate Release 
Tablet of zopiclone was shown in figure no. 3. 
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Figure 3: Drug release profile of immediate release 
tablet 
SUMMARY AND CONCLUSION 
In the present work, the tablet was prepared by wet 
granulation method using the superdisintegrant in the ratio 
of 3%, 4%, 5%. There were three formulation prepared 
using material lactose monohydrate, dibasic calcium 
phosphate, corn starch (maize), sodium starch glycolate, 
magnesium stearate. The granules were prepared and 
subjected to pre- compression analysis. Later Pre-
compression analysis was found and tablet was compressed 
using 7.00 mm round shape, plain both side, standard 
concave Punches by 12 station compression machine 
(Rimek). The manufactured tablets were evaluated for post- 
compression parameters. After observation we found that 
formulation F1 gave less release, so further trail was taken 
by changing the concentration of binder and the final 
formulation F3 was found to be satisfactorily on increasing 
the concentration of superdisintegrant. At last the 
formulation was coated by film coating.  
After preparing the formulation of zopiclone immediate 
release tablet, there were found the great effect of 
superdisintegrant on release of drug. The increased ratio of 
polymer increased the dissolution profile of drug and 
released the drug in less time.  
According to the found result it was concluded that 
immediate release tablet of zopiclone prepared on the above 
ratio is the best formulation in the treatment of short term 
therapy of insomnia.  
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